Literature DB >> 12420719

Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease.

Kazutomi Kanemaru, Hiroshi Yamanouchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12420719     DOI： 10.1007/s00415-002-0753-x

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  7 in total

1.  Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.

Authors:  K Kanemaru; N Kameda; H Yamanouchi
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

2.  18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies.

Authors:  X S Hu; N Okamura; H Arai; M Higuchi; T Matsui; M Tashiro; M Shinkawa; M Itoh; T Ido; H Sasaki
Journal:  Neurology       Date:  2000-11-28       Impact factor: 9.910

3.  Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease.

Authors:  K Blennow; A Wallin; C G Gottfries; A Lekman; I Karlsson; I Skoog; L Svennerholm
Journal:  Neurobiol Aging       Date:  1992 Jan-Feb       Impact factor: 4.673

Review 4.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

5.  In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies.

Authors:  Z Walker; D C Costa; P Ince; I G McKeith; C L Katona
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases.

Authors:  M F Weiner; R C Risser; C M Cullum; L Honig; C White; S Speciale; R N Rosenberg
Journal:  Am J Psychiatry       Date:  1996-10       Impact factor: 18.112
  7 in total
  3 in total

Review 1.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

2.  Bridging molecular genetics and biomarkers in lewy body and related disorders.

Authors:  Gilbert J Ho; Willie Liang; Masaaki Waragai; Kazunari Sekiyama; Eliezer Masliah; Makoto Hashimoto
Journal:  Int J Alzheimers Dis       Date:  2011-07-03

3.  Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.

Authors:  Satoru Morimoto; Masaki Takao; Hiroyuki Hatsuta; Yasushi Nishina; Tadashi Komiya; Renpei Sengoku; Yuta Nakano; Akiko Uchino; Hiroyuki Sumikura; Yuko Saito; Kazutomi Kanemaru; Shigeo Murayama
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.